《大行》大摩降巨子生物(02367.HK)目標價至74元 續籲「增持」
摩根士丹利研究報告指,預期巨子生物(02367.HK)將提高市場推廣力度,以解決負面輿論及恢復品牌勢頭,該行將其2025至2027年的整體銷售預測分別下調13%、9%及7%。其中,預測今年上半年整體銷售增長為18%,旗下品牌可復美(Comfy)為增長12%;下半年整體銷售增長20%,可復美增長14%。另外,將2025至2027年每股盈利預測分別下調14%、9%及7%。
該行將目標價由100元降至74元,維持「增持」評級,因認為內地消費者選擇美容產品時以成分為導向的心態,以及公司在生物技術上的優勢都不會改變;雖然恢復的時間難以預測,但結構性推動因素將持續存在。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.